Drug intelligence / Profile preview

Spirit1

Development stage: Discontinued
Lead developer: Herb Spirit
Administration: Oral

Overview

Spirit1 is an investigational oral nutritional supplement developed by Herb Spirit for amyotrophic lateral sclerosis. It was described in a registered pilot study as a preparation combining phospholipids with medicinal plants; the individual plant constituents, phospholipid composition, and molecular targets were not publicly specified. The planned Phase 1 open-label safety study was withdrawn, and no efficacy or safety results were identified. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02588807))

Beyond the preview

Go deeper on Spirit1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spirit1.

Explore the full profile